An investigation into the effect of advice from the Scottish Medicines Consortium on the use of medicines in Scotland's Health Service

British Journal of Clinical Pharmacology

Volumn 71, Issue 2, 2011, Pages 283-288

  Bennie, Marion ^a,d   Dear, James ^b   Hems, Sharon ^a   Black, Corri ^c   McIver, Laura ^e   Webb, David J ^b  

^a INFORMATION SERVICES DIVISION   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^e HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

Author keywords

Cost effectiveness; Health technology assessment; Scottish Medicines Consortium

Indexed keywords

ANAGRELIDE; ATOMOXETINE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CILOSTAZOL; DESOGESTREL; DICLOFENAC; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFLORNITHINE; ESCITALOPRAM; FROVATRIPTAN; GLYCERYL TRINITRATE; INSULIN ASPART; KETOTIFEN; MACROGOL; MEMANTINE; METFORMIN; NICOTINIC ACID; OLOPATADINE; PIMECROLIMUS; SOLIFENACIN;

ARTICLE; CLINICAL PRACTICE; DRUG UTILIZATION; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; UNITED KINGDOM;

DRUG PRESCRIPTIONS; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; FOCUS GROUPS; HUMANS; INAPPROPRIATE PRESCRIBING; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SCOTLAND; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 78650978188     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03826.x     Document Type: Article

References (10)

1. Dear J, O'Dowd C, Timoney A, Paterson K, Walker A, Webb DJ. Scottish Medicines Consortium: an overview of rapid new drug assessment in Scotland. Scott Med J 2007; 52: 20-6.
2. Cluxton RJ, Jr, Li Z, Heaton PC, Weiss SR, Zuckerman IH, Moomaw CJ, Hsu VD, Rodriguez EM. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program. Pharmacoepidemiol Drug Saf 2005; 14: 1-9.
3. Weatherby LB, Nordstrom BL, Fife D, Walker AM. The impact of wording in 'Dear doctor' letters and in black box labels. Clin Pharmacol Ther 2002; 72: 735-42.
4. NHS Information Centre. Use of NICE appraised medicines in the NHS in England - experimental statistics. Available at (last accessed 25 August 2010).
5. Scottish Intercollegiate Guidelines Network Guideline 89. Diagnosis and management of peripheral arterial disease. Available at (last accessed 25 August 2010).
6. Managing the use of medicines in hospitals. Available at (last accessed 25 August 2010).
7. Community Health Index (CHI) Initiative. Available at (last accessed 25 August 2010).
8. Scottish Executive. Introduction and availability of newly licensed medicines in the NHS in Scotland. Chief Executive's letter; 17: 2010.
9. Scottish Executive. Scottish Medicines Consortium (SMC) advice and single technology appraisals from the National Institute of Health and Clinical Excellence. Health Directorate letter; 29: 2006.
10. Scottish Executive. A strengthened role for the Scottish Medicines Consortium (SMC). Health Directorate letter; 60: 2003.